Comparative Genomics and Proteomics in Drug Discovery: Vol 58 / Edition 1

by John Parrington, Kevin Coward

Overview

Comparative Genomics and Proteomics in Drug Discovery gives an overview of how emerging genomic and proteomic technologies are making significant contributions to global drug discovery programs, and in particular the key role that comparative genomics and proteomics play within this strategy. Each chapter is written by respected authorities, with hands-on experience, from both academic and pharmaceutical backgrounds.

Product Details

ISBN-13:	9780415396530
Publisher:	Taylor & Francis
Publication date:	11/09/2006
Series:	Society for Experimental Biology Series
Pages:	164
Product dimensions:	6.12(w) x 9.19(h) x (d)

About the Author

John Parrington and Kevin Coward, Department of Pharmacology, University of Oxford, UK.

Table of Contents

1. Comparative Genomics and Drug Discovery in Trypanosomatids 2. The Practical Implications of Comparative Kinetoplastid Genomics 3. The Relevance of Host Genes in Malaria 4. Nicotinic Acetylcholine Receptors as Drug/Chemical Targets, Contributions from Comparative Genomics, Forward and Reverse Genetics 5. Discovery of Novel Sodium Channel Inhibitors - A Gene Family-Based Approach 6. 'Omics' in Translational Medicine : Are They Lost in Translation? 7. Drug-Target Discovery In Silico : Using the Web to Identify Novel Molecular Targets for Drug Action

Editorial Reviews

Reviewer: Xiaobo Zhong, Ph.D.(University of Kansas Medical Center)
Description: Comparative genomics is the study of relationships between the genomes of different species or strains. It exploits both similarities and differences in the protein, RNA, and regulatory regions of different organisms. This book arose from a symposium as part of the Annual Meeting of the Society for Experimental Biology (UK) in 2005. Each chapter is written by respected experts from both academic and pharmaceutical backgrounds.
Purpose: The purpose is to provide an overview of how genomic and proteomic technologies are making significant contributions to global drug discovery programs and, in particular, how comparative genomics and proteomics play a key role in this strategy.
Audience: According to the editor, the book targets students, researchers, and academics in related areas of biomedicine and pharmaceutics as well as a more general readership interested in specific applications of genomic and proteomic technologies.
Features: Seven concise chapters make up the book. Chapters 1 and 2 describe how comparative genomics is being used to assist in drug discovery against the main human pathogens responsible for a wide range of human diseases. Chapters 3 and 4 discuss how comparative genomics has contributed to the study of a group of host genes (receptors) as drug targets for a number of human diseases such as malaria and autoimmune disorders. Chapter 5 describes how genomic and proteomic strategies are being used in isolating novel sodium channel inhibitors as potential drugs for improved analgesics. Chapters 6 and 7 discuss how information resulting from genomic and proteomic studies can be translated into understanding disease processes, effective management of therapy, and drug target discovery.
Assessment: Using comparative genomics with emerging genomic and proteomic technologies is a relatively new but rapidly growing approach to identifying drug targets and to discovering new drugs. Information generated by this strategy needs to be frequently updated. I anticipate that more books in this area will be published soon.

Doody's Review Service

Reviewer: Xiaobo Zhong, Ph.D.(University of Kansas Medical Center)
Description: Comparative genomics is the study of relationships between the genomes of different species or strains. It exploits both similarities and differences in the protein, RNA, and regulatory regions of different organisms. This book arose from a symposium as part of the Annual Meeting of the Society for Experimental Biology (UK) in 2005. Each chapter is written by respected experts from both academic and pharmaceutical backgrounds.
Purpose: The purpose is to provide an overview of how genomic and proteomic technologies are making significant contributions to global drug discovery programs and, in particular, how comparative genomics and proteomics play a key role in this strategy.
Audience: According to the editor, the book targets students, researchers, and academics in related areas of biomedicine and pharmaceutics as well as a more general readership interested in specific applications of genomic and proteomic technologies.
Features: Seven concise chapters make up the book. Chapters 1 and 2 describe how comparative genomics is being used to assist in drug discovery against the main human pathogens responsible for a wide range of human diseases. Chapters 3 and 4 discuss how comparative genomics has contributed to the study of a group of host genes (receptors) as drug targets for a number of human diseases such as malaria and autoimmune disorders. Chapter 5 describes how genomic and proteomic strategies are being used in isolating novel sodium channel inhibitors as potential drugs for improved analgesics. Chapters 6 and 7 discuss how information resulting from genomic and proteomic studies can be translated into understanding disease processes, effective management of therapy, and drug target discovery.
Assessment: Using comparative genomics with emerging genomic and proteomic technologies is a relatively new but rapidly growing approach to identifying drug targets and to discovering new drugs. Information generated by this strategy needs to be frequently updated. I anticipate that more books in this area will be published soon.